Tue, May 20, 10:06 AM (32 days ago)
### AIBiotics Therapies, Inc. (AIBT) Q1 2025 Financial Summary **Company Overview:** AIBiotics Therapies, Inc. (AIBT) is a Nevada-based company focused on developing advanced engineering and design techniques for new products. The company has experienced significant financial challenges, including negative operating cash flows and substantial operating losses since its inception. **Q1 2025 Financial Performance:** **Revenue and Profit Margins:** - **Revenue:** $2,183,000, marking the first revenue recorded by the company. - **Gross Profit:** $2,183,000, as there were no costs of goods sold. - **Operating Expenses:** $531,647,000, primarily consisting of general and administrative expenses, including consulting fees, stock-based compensation, board compensation, and legal and professional services. - **Net Loss:** $591,397,000, reflecting a significant increase from the $425,942,000 net loss in Q1 2024. - **Net Loss per Share:** $(0.01), compared to $(0.03) in Q1 2024. **Cash Flow:** - **Operating Activities:** Net cash used in operating activities was $(28,360,000), an improvement from $(73,709,000) in Q1 2024. - **Investing Activities:** No cash flows from investing activities. - **Financing Activities:** No cash flows from financing activities in Q1 2025, compared to $165,000 in Q1 2024. **Balance Sheet Highlights:** - **Current Assets:** $156,737,000, down from $185,097,000 at the end of 2024. - **Current Liabilities:** $5,101,372,000, including significant related party accrued expenses and convertible notes payable. - **Working Capital Deficit:** $4,944,635,000, indicating substantial liquidity challenges. - **Total Assets:** $1,264,401,000, down from $1,456,995,000 at the end of 2024. - **Total Liabilities and Stockholders' Deficit:** $1,264,401,000, reflecting a deficit of $(3,836,971,000). **Earnings Changes and Trends:** - **Revenue Growth:** The company recorded its first revenue, indicating a potential shift towards generating sales. - **Operating Expenses:** Increased by 47% due to higher legal and professional services, board compensation, product development, and consulting fees. - **Interest Expense:** Decreased by 5%, primarily due to the absence of debt discount amortization. **Future Operations and Uncertainties:** - **Going Concern:** The company's ability to continue as a going concern is questionable due to significant operating losses and liquidity issues. - **Funding:** The company plans to fund operations through cash on hand and additional financing. - **Strategic Initiatives:** Management is actively pursuing equity financing and developing the company's business to address liquidity problems. **Conclusion:** AIBiotics Therapies, Inc. faces significant financial challenges, including substantial operating losses and liquidity issues. While the company recorded its first revenue in Q1 2025, the net loss increased, and the working capital deficit remains substantial. Management is focused on securing additional financing and developing the business to address these challenges. The company's future operations and financial health will depend on its ability to generate revenue, control expenses, and secure necessary funding.